Overview

The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia

Status:
Recruiting
Trial end date:
2022-09-20
Target enrollment:
Participant gender:
Summary
This is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of Huaiqihuang granule for treatment to children with chronic primary immune thrombocytopenia (Qi Yin deficiency).
Phase:
Phase 4
Details
Lead Sponsor:
Qidong Gaitianli Medicines Co., Ltd
Collaborator:
Huazhong University of Science and Technology